CYCLOPHOSPHAMIDE Side Effects

6969626-5 | Pneumococcal Infection
on Sep 03, 2010 Female patient from UNITED KINGDOM , child 1 years of age, was diagnosed with choroid plexus carcinoma and was treated with Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: pneumococcal infection. Cyclophosphamide dosage: Course:6;days 2 And 3. During the same period patient was treated with ETOPOSIDE (Course:6;at 21-day Intervals With Etoposide Days 1-5,) (View Etoposide Review and Etoposide Label ), VINCRISTINE SULFATE (Course:6) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6969497-7 | Acute Myocardial Infarction, Acute Pulmonary Oedema, Cardiac Failure Congestive, Cerebrovascular Accident, Hypotension, Lacunar Infarction
Patient was taking Cyclophosphamide (View Usage). Patient had the following side effects: acute myocardial infarction, acute pulmonary oedema, cardiac failure congestive, cerebrovascular accident, hypotension, lacunar infarction on Sep 07, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 141.1 lb, . Cyclophosphamide dosage: 982 Mg. During the same period patient was treated with DOXORUBICIN HYDROCHLORIDE (98 Mg) (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), TAXOL (281 Mg) (View Taxol Review and Taxol Label ). Patient was hospitalized.

6968999-7 | Alanine Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Blood Sodium Decreased, Epstein-barr Virus Associated Lymphoproliferative Disorder, Epstein-barr Virus Test Positive, Gastrointestinal Haemorrhage, Haemodialysis, Hepatosplenomegaly
Adverse event was reported on Aug 31, 2010 by a Male patient taking Cyclophosphamide (View Usage) (Dosage: ) was diagnosed with lymphoproliferative disorder, crohn's disease (What is crohn's disease?), epstein-barr virus infection and. Location: UNITED KINGDOM , 15 years of age, After Cyclophosphamide was administered, patient had the following side effects: alanine aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood sodium decreased, epstein-barr virus associated lymphoproliferative disorder, epstein-barr virus test positive, gastrointestinal haemorrhage, haemodialysis, hepatosplenomegaly. During the same period patient was treated with AZATHIOPRINE (View Azathioprine Review and Azathioprine Label ), GANCICLOVIR SODIUM (View Ganciclovir Sodium Review and Ganciclovir Sodium Label ), MESALAZINE (View Mesalazine Review and Mesalazine Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ).

6968908-0 | Alanine Aminotransferase Increased, Animal Bite, Ascites, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Potassium Decreased, Cardiac Failure Congestive, Cellulitis, Glucose Urine Present
on Sep 03, 2010 Male patient from UNITED STATES , weighting 181.2 lb, was treated with Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, animal bite (What is animal bite?), ascites, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood potassium decreased, cardiac failure congestive, cellulitis (What is cellulitis?), glucose urine present. Cyclophosphamide dosage: . During the same period patient was treated with DOXORUBICIN HYDROCHLORIDE (97 Mg) (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), PREDNISONE (80 Mg) (View Prednisone Review and Prednisone Label ), RITUXIMAB (MOAB C2B8 ANTI CD20, CHIMERIC) (728 Mg) (View Rituximab (moab C2b8 Anti Cd20, Chimeric) Review and Rituximab (moab C2b8 Anti Cd20, Chimeric) Label ), VINCRISTINE SULFATE (2 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.


6968907-9 | Febrile Neutropenia, Haemoglobin Decreased, Platelet Count Decreased, Pulmonary Mycosis, White Blood Cell Count Decreased
on Sep 03, 2010 Female patient from UNITED STATES , weighting 157.6 lb, was treated with Cyclophosphamide (View Usage). Patient had the following side effects: febrile neutropenia, haemoglobin decreased, platelet count decreased, pulmonary mycosis, white blood cell count decreased. Cyclophosphamide dosage: 1870 Mg. During the same period patient was treated with CYTARABINE (1120 Mg) (View Cytarabine Review and Cytarabine Label ), DEXAMETHASONE (280 Mg) (View Dexamethasone Review and Dexamethasone Label ), DOXORUBICIN HYDROCHLORIDE (141 Mg) (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), METHOTREXATE (45 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARAGINASE (K H) (9350 Iu) (View Peg-l- Asparaginase (k -h) Review and Peg-l- Asparaginase (k -h) Label ), THIOGUANINE (1520 Mg) (View Thioguanine Review and Thioguanine Label ), VINCRISTINE SULFATE (10 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6968632-4 | Febrile Neutropenia, Haemoglobin Decreased, Oropharyngeal Pain, Platelet Count Decreased
Patient was taking Cyclophosphamide (View Usage). After Cyclophosphamide was administered, patient had the following side effects: febrile neutropenia, haemoglobin decreased, oropharyngeal pain, platelet count decreased on Sep 03, 2010 from UNITED STATES Additional patient health information: Female patient , 69 years of age, weighting 130.1 lb, was diagnosed with breast cancer (What is breast cancer?) and. Cyclophosphamide dosage: 951 Mg Every Other Week - Last Dose Iv. During the same period patient was treated with DOXORUBICIN HCL (95 Mg Every Other Week - Last Dose Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), AVASTIN (221 Mg Iv) (View Avastin Review and Avastin Label ). Patient was hospitalized.

6968564-1 | Abdominal Pain Upper, Anxiety, Face Oedema, Headache, Oxygen Saturation Decreased, Vomiting
Adverse event was reported on Aug 27, 2010 by a Male patient taking Cyclophosphamide (View Usage) (Dosage: ) was diagnosed with acute lymphocytic leukaemia and. Location: POLAND , child 11 years of age, weighting 110.2 lb, Patient experienced the following unwanted or unexpected effects: abdominal pain upper, anxiety (What is anxiety?), face oedema, headache (What is headache?), oxygen saturation decreased, vomiting. During the same period patient was treated with MESNA (View Mesna Review and Mesna Label ), ZOFRAN (View Zofran Review and Zofran Label ), SYLIMAROL (View Sylimarol Review and Sylimarol Label ), HEPATIL (View Hepatil Review and Hepatil Label ). Patient was hospitalized.

6967952-7 | Anxiety, Back Pain, Face Oedema, Fluid Retention, Vomiting
on Aug 27, 2010 Female patient from POLAND , child 3 years of age, weighting 33.07 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Cyclophosphamide (View Usage). Patient had the following side effects: anxiety (What is anxiety?), back pain (What is back pain?), face oedema, fluid retention, vomiting. Cyclophosphamide dosage: . During the same period patient was treated with MESNA (View Mesna Review and Mesna Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), ZOFRAN (View Zofran Review and Zofran Label ). Patient was hospitalized.

6967602-X | Venoocclusive Liver Disease
on Sep 01, 2010 Male patient from , 22 years of age, was diagnosed with bone marrow conditioning regimen, prophylaxis and was treated with Cyclophosphamide (View Usage). After Cyclophosphamide was administered, patient had the following side effects: venoocclusive liver disease. Cyclophosphamide dosage: . During the same period patient was treated with BUSULFAN (View Busulfan Review and Busulfan Label ), HEPARIN (View Heparin Review and Heparin Label ), GLUTAMINE (View Glutamine Review and Glutamine Label ), URSODIOL (View Ursodiol Review and Ursodiol Label ).

6966735-1 | Venoocclusive Liver Disease
Patient was taking Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: venoocclusive liver disease on Sep 02, 2010 from UNITED STATES Additional patient health information: Male patient , 22 years of age, . Cyclophosphamide dosage: . During the same period patient was treated with BUSULFAN (View Busulfan Review and Busulfan Label ).

6966434-6 | Malignant Neoplasm Progression, Menopause, Sepsis, Vaginal Obstruction
Adverse event was reported on Aug 26, 2010 by a Female patient taking Cyclophosphamide (View Usage) (Dosage: ) was diagnosed with mycosis fungoides and. Location: TAIWAN, PROVINCE OF CHINA , 42 years of age, Patient had the following side effects: malignant neoplasm progression, menopause (What is menopause?), sepsis (What is sepsis?), vaginal obstruction. During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6965177-2 | Reversible Posterior Leukoencephalopathy Syndrome
on Aug 27, 2010 Female patient from UNITED KINGDOM , 60 years of age, was diagnosed with t-cell lymphoma and was treated with Cyclophosphamide (View Usage). After Cyclophosphamide was administered, patient had the following side effects: reversible posterior leukoencephalopathy syndrome. Cyclophosphamide dosage: . During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6963775-3 | Lung Disorder, Multi-organ Failure, Septic Shock
on Aug 25, 2010 Male patient from FRANCE , 71 years of age, was diagnosed with vasculitis necrotising, microscopic polyangiitis and was treated with Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: lung disorder, multi-organ failure, septic shock. Cyclophosphamide dosage: . During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), MABTHERA (View Mabthera Review and Mabthera Label ). Patient was hospitalized.

6963678-4 | Dysarthria, Hemiparesis, Monoplegia, Oesophageal Disorder, Sensory Loss, Stomatitis, Swelling Face, Viith Nerve Paralysis
Patient was taking Cyclophosphamide (View Usage). Patient had the following side effects: dysarthria, hemiparesis, monoplegia, oesophageal disorder, sensory loss, stomatitis, swelling face, viith nerve paralysis on Aug 10, 2010 from BELGIUM Additional patient health information: Male patient , 13 years of age, was diagnosed with acute lymphocytic leukaemia and. Cyclophosphamide dosage: (1000 Mg/m2, Day2 Intravenous. During the same period patient was treated with CYTARABINE ((75 Mg/m2, Days 3-6 + Days 10-13) Intravenous; (30 Mg) Intrathecal) (View Cytarabine Review and Cytarabine Label ), METHOTREXATE ((12 Mg) Intrathecal) (View Methotrexate Review and Methotrexate Label ), THIOGUANINE (THIOGUANINE) (THIOGUANINE) (View Thioguanine (thioguanine) (thioguanine) Review and Thioguanine (thioguanine) (thioguanine) Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), COTRIMOXAZOLE (BACTRIM /00086101/) (BACTRIM /00086101/) (View Cotrimoxazole (bactrim /00086101/) (bactrim /00086101/) Review and Cotrimoxazole (bactrim /00086101/) (bactrim /00086101/) Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ).

6963644-9 | Renal Failure Acute
Adverse event was reported on Aug 25, 2010 by a Male patient taking Cyclophosphamide (View Usage) (Dosage: ) was diagnosed with rhabdoid tumour of the kidney and. Location: JAPAN , 30 years of age, After Cyclophosphamide was administered, patient had the following side effects: renal failure acute. During the same period patient was treated with IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ).

6963634-6 | Ovarian Failure, Pelvic Abscess
on Aug 27, 2010 Female patient from TAIWAN, PROVINCE OF CHINA , 42 years of age, was diagnosed with t-cell lymphoma and was treated with Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: ovarian failure, pelvic abscess. Cyclophosphamide dosage: . During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), PREDNISONE (View Prednisone Review and Prednisone Label ).

6962726-5 | Device Related Infection, Muscle Contractions Involuntary, Pneumocystis Jiroveci Pneumonia, Staphylococcal Bacteraemia, Tic
on Aug 26, 2010 Male patient from UNITED KINGDOM , 13 years of age, was diagnosed with epstein-barr virus associated lymphoproliferative disorder and was treated with Cyclophosphamide (View Usage). Patient had the following side effects: device related infection, muscle contractions involuntary, pneumocystis jiroveci pneumonia, staphylococcal bacteraemia, tic (What is tic?). Cyclophosphamide dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), CAELYX (View Caelyx Review and Caelyx Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), METHOTREXATE (Took 5 Doses) (View Methotrexate Review and Methotrexate Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), THIOGUANINE (View Thioguanine Review and Thioguanine Label ). Patient was hospitalized.

6960991-1 | Cerebrovascular Spasm, Neurological Symptom, Reversible Posterior Leukoencephalopathy Syndrome
Patient was taking Cyclophosphamide (View Usage). After Cyclophosphamide was administered, patient had the following side effects: cerebrovascular spasm, neurological symptom, reversible posterior leukoencephalopathy syndrome on Aug 23, 2010 from NETHERLANDS Additional patient health information: Female patient , 48 years of age, was diagnosed with aplastic anaemia and. Cyclophosphamide dosage: 350 Mg, Bid. Patient was hospitalized.

6960669-4 | Hepatitis B
Adverse event was reported on Aug 26, 2010 by a Male patient taking Cyclophosphamide (View Usage) (Dosage: ) was diagnosed with b-cell lymphoma and. Location: FRANCE , 75 years of age, Patient experienced the following unwanted or unexpected effects: hepatitis b (What is hepatitis b?). During the same period patient was treated with MABTHERA (View Mabthera Review and Mabthera Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), HYPERIUM (View Hyperium Review and Hyperium Label ), TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ), DOMPERIDONE (View Domperidone Review and Domperidone Label ), HYDROXYZINE (View Hydroxyzine Review and Hydroxyzine Label ), STILNOX /FRA/ (View Stilnox /fra/ Review and Stilnox /fra/ Label ). Patient was hospitalized.

6956966-9 | Asthenia, Culture Wound Positive, Dehydration, Haemoglobin Decreased, Hypotension, Impaired Healing, Neutropenia, Pneumonia, Pyrexia
on Aug 27, 2010 Female patient from UNITED STATES , weighting 176.4 lb, was treated with Cyclophosphamide (View Usage). Patient had the following side effects: asthenia, culture wound positive, dehydration, haemoglobin decreased, hypotension, impaired healing, neutropenia, pneumonia (What is pneumonia?), pyrexia. Cyclophosphamide dosage: 1116 Mg. During the same period patient was treated with DOXORUBICIN HYDROCHLORIDE (112 Mg) (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ). Patient was hospitalized.

6945504-2 | Cellulitis, Neutropenia
on Aug 23, 2010 Female patient from UNITED STATES , 43 years of age, was diagnosed with breast cancer (What is breast cancer?) and was treated with Cyclophosphamide (View Usage). After Cyclophosphamide was administered, patient had the following side effects: cellulitis (What is cellulitis?), neutropenia. Cyclophosphamide dosage: . During the same period patient was treated with DOCETAXEL (View Docetaxel Review and Docetaxel Label ), TRIPTORELIN (View Triptorelin Review and Triptorelin Label ). Patient was hospitalized.

6943604-4 | Blood Bilirubin Increased, Clostridium Difficile Colitis, Diarrhoea, Febrile Neutropenia, Neutropenic Sepsis, Pyrexia, Thrombocytopenia
Patient was taking Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: blood bilirubin increased, clostridium difficile colitis, diarrhoea, febrile neutropenia, neutropenic sepsis, pyrexia, thrombocytopenia on Aug 19, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 40 years of age, was diagnosed with pancreatic carcinoma metastatic, antibiotic prophylaxis, neutropenic sepsis, infection (What is infection?) and. Cyclophosphamide dosage: . During the same period patient was treated with MEROPENEM (View Meropenem Review and Meropenem Label ). Patient was hospitalized.

6943603-2 | Dementia
Adverse event was reported on Aug 19, 2010 by a Female patient taking Cyclophosphamide (View Usage) (Dosage: ) . Location: FRANCE , 90 years of age, Patient had the following side effects: dementia (What is dementia?). During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ). Patient was hospitalized and became disabled.

6943602-0 | Bronchopulmonary Aspergillosis, Multi-organ Failure, Septic Shock
on Aug 17, 2010 Male patient from NETHERLANDS , 61 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Cyclophosphamide (View Usage). After Cyclophosphamide was administered, patient had the following side effects: bronchopulmonary aspergillosis, multi-organ failure, septic shock. Cyclophosphamide dosage: Gereduceerde Dosis. During the same period patient was treated with METHYLPREDNISOLONE (Dag 1-14 Van De Cyclus. 7 Dagen Gebruikt Deze Cyclus, Reden Onbekend.) (View Methylprednisolone Review and Methylprednisolone Label ), VINCRISTINE SULFATE (Vroegtijdig Gestopt, Op 14 Juni 2010 (cyclus 4), Reden Onbekend.) (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN HCL (Gereduceerde Dosis) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ETOPOSIDE (Dag 1-3. Gereduceerde Dosis) (View Etoposide Review and Etoposide Label ), PROCARBAZINE (Dag 1-7.) (View Procarbazine Review and Procarbazine Label ). Patient was hospitalized.

6943536-1 | Abdominal Pain, Activated Partial Thromboplastin Time Prolonged, Atrial Flutter, Body Temperature Increased, Cardio-respiratory Arrest, Chills, Clostridium Test Positive, Condition Aggravated, Diarrhoea
on Aug 25, 2010 Male patient from UNITED STATES , weighting 169.3 lb, was treated with Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), activated partial thromboplastin time prolonged, atrial flutter, body temperature increased, cardio-respiratory arrest, chills, clostridium test positive, condition aggravated, diarrhoea. Cyclophosphamide dosage: 1340 Mg. During the same period patient was treated with DOXORUBICIN HYDROCHLORIDE (72 Mg) (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), ETOPOSIDE (360 Mg) (View Etoposide Review and Etoposide Label ), PREDNISONE (1100 Mg) (View Prednisone Review and Prednisone Label ), RITUXIMAB (MOAB C2B8 ANTI CD20, CHIMERIC) (650 Mg) (View Rituximab (moab C2b8 Anti Cd20, Chimeric) Review and Rituximab (moab C2b8 Anti Cd20, Chimeric) Label ), VINCRISTINE SULFATE (2.8 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6943519-1 | Dry Mouth
Patient was taking Cyclophosphamide (View Usage). Patient had the following side effects: dry mouth on Aug 25, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 227.1 lb, . Cyclophosphamide dosage: 1302 Mg. During the same period patient was treated with DOXORUBICIN HCL (130.2 Mg) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ).

6943495-1 | Bone Marrow Failure, Diarrhoea, Oral Disorder, Parkinsonism, Vomiting
Adverse event was reported on Aug 17, 2010 by a Male patient taking Cyclophosphamide (View Usage) (Dosage: ) was diagnosed with pineal neoplasm, prophylaxis and. Location: JAPAN , 14 years of age, After Cyclophosphamide was administered, patient had the following side effects: bone marrow failure, diarrhoea, oral disorder, parkinsonism, vomiting. During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), HYDROCORTISONE (View Hydrocortisone Review and Hydrocortisone Label ).

6942326-3 | Hemiparesis
on Aug 19, 2010 Male patient from BELGIUM , 13 years of age, weighting 134.5 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: hemiparesis. Cyclophosphamide dosage: On Day 1. During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), MESNA (View Mesna Review and Mesna Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), BACTRIM (View Bactrim Review and Bactrim Label ), ERWINASE (1 Df = 20,000 U/m2) (View Erwinase Review and Erwinase Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), THIOGUANINE (Days 1-14) (View Thioguanine Review and Thioguanine Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

6941562-X | Splenic Artery Aneurysm
on Aug 13, 2010 Female patient from UNITED KINGDOM , 61 years of age, was diagnosed with immunosuppression and was treated with Cyclophosphamide (View Usage). Patient had the following side effects: splenic artery aneurysm. Cyclophosphamide dosage: Unk. During the same period patient was treated with PREDNISONE (WATSON LABORATORIES) (Unk) (View Prednisone (watson Laboratories) Review and Prednisone (watson Laboratories) Label ), AZATHIOPRINE (Unk) (View Azathioprine Review and Azathioprine Label ). Patient was hospitalized.

6941468-6 | Abdominal Pain, Blood Culture Positive, Breath Sounds Abnormal, Candidiasis, Dyspnoea, Hypotension, Post Procedural Complication, Pyrexia, Staphylococcal Infection
Patient was taking Cyclophosphamide (View Usage). After Cyclophosphamide was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), blood culture positive, breath sounds abnormal, candidiasis, dyspnoea, hypotension, post procedural complication, pyrexia, staphylococcal infection (What is staphylococcal infection?) on Aug 24, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 130.7 lb, . Cyclophosphamide dosage: 1760 Mg. During the same period patient was treated with CYTARABINE (1040 Mg) (View Cytarabine Review and Cytarabine Label ), MERCAPTOPURINE (1400 Mg) (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (45 Mg) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE SULFATE (2 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6940656-2 |
Adverse event was reported on Aug 16, 2010 by a Female patient taking Cyclophosphamide (View Usage) (Dosage: ) was diagnosed with breast cancer (What is breast cancer?) and. Location: JAPAN , 70 years of age, . During the same period patient was treated with FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), EPIRUBICIN HYDROCHLORIDE (View Epirubicin Hydrochloride Review and Epirubicin Hydrochloride Label ).

6940325-9 | Cardiomyopathy
on Aug 17, 2010 Female patient from UNITED KINGDOM , 81 years of age, was diagnosed with non-hodgkin's lymphoma and was treated with Cyclophosphamide (View Usage). Patient had the following side effects: cardiomyopathy (What is cardiomyopathy?). Cyclophosphamide dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), MITOXANTRONE (View Mitoxantrone Review and Mitoxantrone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6939254-6 | Cerebral Infarction
on Aug 17, 2010 Male patient from NETHERLANDS , 56 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Cyclophosphamide (View Usage). After Cyclophosphamide was administered, patient had the following side effects: cerebral infarction. Cyclophosphamide dosage: Gereduceerde Dosis. During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ETOPOSIDE (Dag 1-3gereduceerde Dosis) (View Etoposide Review and Etoposide Label ), PROCARBAZINE (Dag 1-7) (View Procarbazine Review and Procarbazine Label ), METHYLPREDNISOLONE (8 Dagen Gebruikt In Deze Cyclus (normaal Dag 1-14 Van De Cyclus).) (View Methylprednisolone Review and Methylprednisolone Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6937697-8 | Acute Lymphocytic Leukaemia, Blood Albumin Decreased, Blood Alkaline Phosphatase Increased, Blood Creatinine Decreased, Blood Glucose Decreased, Blood Lactate Dehydrogenase Increased, Blood Sodium Decreased, Blood Urea Decreased, Gamma-glutamyltransferase Increased
Patient was taking Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: acute lymphocytic leukaemia, blood albumin decreased, blood alkaline phosphatase increased, blood creatinine decreased, blood glucose decreased, blood lactate dehydrogenase increased, blood sodium decreased, blood urea decreased, gamma-glutamyltransferase increased on Aug 13, 2010 from JAPAN Additional patient health information: Female patient , 56 years of age, was diagnosed with acute lymphocytic leukaemia, breast cancer recurrent and. Cyclophosphamide dosage: . During the same period patient was treated with FARESTON (View Fareston Review and Fareston Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ), FURTULON (View Furtulon Review and Furtulon Label ), HYSRONE H (View Hysrone H Review and Hysrone H Label ), TRASTUZUMAB (View Trastuzumab Review and Trastuzumab Label ). Patient was hospitalized.

6937538-9 | Renal Impairment
Adverse event was reported on Aug 12, 2010 by a Male patient taking Cyclophosphamide (View Usage) (Dosage: ) was diagnosed with b-cell lymphoma and. Location: NETHERLANDS , 55 years of age, Patient had the following side effects: renal impairment. During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ).

6937526-2 | Tremor
on Aug 12, 2010 Female patient from GERMANY , 66 years of age, weighting 143.3 lb, was diagnosed with breast cancer (What is breast cancer?), hypertension, cystitis and was treated with Cyclophosphamide (View Usage). After Cyclophosphamide was administered, patient had the following side effects: tremor. Cyclophosphamide dosage: . During the same period patient was treated with TAXOTERE (View Taxotere Review and Taxotere Label ), BISOHEXAL (View Bisohexal Review and Bisohexal Label ), ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), UROMITEXAN (View Uromitexan Review and Uromitexan Label ).

6937485-2 | Progressive Multifocal Leukoencephalopathy, Pyrexia
on Aug 12, 2010 Male patient from UNITED KINGDOM , 71 years of age, was diagnosed with waldenstrom's macroglobulinaemia and was treated with Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: progressive multifocal leukoencephalopathy, pyrexia. Cyclophosphamide dosage: . During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6937073-8 | Reversible Posterior Leukoencephalopathy Syndrome
Patient was taking Cyclophosphamide (View Usage). Patient had the following side effects: reversible posterior leukoencephalopathy syndrome on Aug 13, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 60 years of age, . Cyclophosphamide dosage: . During the same period patient was treated with DOXORUBICIN HYDROCHLORIDE (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ).

6936894-5 | Reversible Posterior Leukoencephalopathy Syndrome
Adverse event was reported on Aug 19, 2010 by a Female patient taking Cyclophosphamide (View Usage) (Dosage: ) . Location: UNITED KINGDOM , 60 years of age, After Cyclophosphamide was administered, patient had the following side effects: reversible posterior leukoencephalopathy syndrome. During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6936011-1 | Granulocytes Abnormal, Neutrophil Count Decreased
on Aug 18, 2010 Female patient from UNITED STATES , 56 years of age, weighting 149.9 lb, was diagnosed with breast cancer metastatic and was treated with Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: granulocytes abnormal, neutrophil count decreased. Cyclophosphamide dosage: Over 60min On Day 3. During the same period patient was treated with DOXORUBICIN HCL (Ivp Over 15min On Day 3) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ).

6935763-4 | Neutrophil Count Abnormal, Platelet Count Abnormal, White Blood Cell Count Abnormal
on Aug 19, 2010 Female patient from UNITED STATES , weighting 198.0 lb, was treated with Cyclophosphamide (View Usage). Patient had the following side effects: neutrophil count abnormal, platelet count abnormal, white blood cell count abnormal. Cyclophosphamide dosage: 4000 Mg. During the same period patient was treated with CYTARABINE (2400 Mg) (View Cytarabine Review and Cytarabine Label ), MERCAPTOPURINE (3400 Mg) (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (60 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARAGINASE (K H) (5000 Mg) (View Peg-l- Asparaginase (k -h) Review and Peg-l- Asparaginase (k -h) Label ), VINCRISTINE SULFATE (8 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ).

6935760-9 | Platelet Count Abnormal
Patient was taking Cyclophosphamide (View Usage). After Cyclophosphamide was administered, patient had the following side effects: platelet count abnormal on Aug 19, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 143.1 lb, . Cyclophosphamide dosage: 3800 Mg. During the same period patient was treated with CYTARABINE (2240 Mg) (View Cytarabine Review and Cytarabine Label ), MERCAPTOPURINE (3200 Mg) (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (45 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARAGINASE (K H) (9400 Mg) (View Peg-l- Asparaginase (k -h) Review and Peg-l- Asparaginase (k -h) Label ), VINCRISTINE SULFATE (8 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ).

6934584-6 | Intestinal Ischaemia, Large Intestinal Haemorrhage, Mucosal Erosion, Thrombotic Microangiopathy
Adverse event was reported on Aug 13, 2010 by a Male patient taking Cyclophosphamide (View Usage) (Dosage: Unk) was diagnosed with prophylaxis against transplant rejection, atrial fibrillation (What is atrial fibrillation?) and. Location: ITALY , 59 years of age, Patient experienced the following unwanted or unexpected effects: intestinal ischaemia, large intestinal haemorrhage, mucosal erosion, thrombotic microangiopathy. During the same period patient was treated with TICLOPIDINE HCL (Unk) (View Ticlopidine Hcl Review and Ticlopidine Hcl Label ).

6933103-8 | Cerebrovascular Accident
on Aug 13, 2010 Female patient from UNITED STATES , 52 years of age, weighting 202.8 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Cyclophosphamide (View Usage). Patient had the following side effects: cerebrovascular accident. Cyclophosphamide dosage: Interrupted On 09jul2010. During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ZOFRAN (View Zofran Review and Zofran Label ), LITHIUM (View Lithium Review and Lithium Label ), PROZAC (View Prozac Review and Prozac Label ), COMPAZINE (View Compazine Review and Compazine Label ), FLONASE (View Flonase Review and Flonase Label ), PROAIR HFA (View Proair Hfa Review and Proair Hfa Label ), FLOVENT (View Flovent Review and Flovent Label ). Patient was hospitalized.

6933041-0 | Acute Respiratory Distress Syndrome, Pneumocystis Jiroveci Pneumonia
on Aug 18, 2010 Male patient from UNITED STATES , weighting 26.01 lb, was treated with Cyclophosphamide (View Usage). After Cyclophosphamide was administered, patient had the following side effects: acute respiratory distress syndrome, pneumocystis jiroveci pneumonia. Cyclophosphamide dosage: 570 Mg. During the same period patient was treated with CYTARABINE (50 Mg) (View Cytarabine Review and Cytarabine Label ), DEXAMETHASONE (1.6 Mg) (View Dexamethasone Review and Dexamethasone Label ), MERCAPTOPURINE (1.6 Mg) (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (34 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARAGINASE (PEGASPARGASE, ONCOSPAR) (1350 Unit) (View Peg-l- Asparaginase (pegaspargase, Oncospar) Review and Peg-l- Asparaginase (pegaspargase, Oncospar) Label ), VINCRISTINE SULFATE (.8 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6932748-9 | Skin Necrosis
Patient was taking Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: skin necrosis on Aug 10, 2010 from NETHERLANDS Additional patient health information: Male patient , 72 years of age, weighting 165.3 lb, was diagnosed with non-hodgkin's lymphoma and. Cyclophosphamide dosage: 1400mg Eenmalig. During the same period patient was treated with DOXORUBICIN HCL (95mg Eenmalig) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE SULFATE (2mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ), PREDNISOLONE (100mg 1dd Gedurende 5 Dagen) (View Prednisolone Review and Prednisolone Label ), NEULASTA (0,6ml Eenmalig) (View Neulasta Review and Neulasta Label ), NOVORAPID (3dd 10-8-6ie) (View Novorapid Review and Novorapid Label ), INSULIN DETEMIR (1dd22ie) (View Insulin Detemir Review and Insulin Detemir Label ), DURAGESIC 100 (12ug/uur 1x/3 Dagen) (View Duragesic-100 Review and Duragesic-100 Label ). Patient was hospitalized.

6931018-2 | Dyspnoea, Hypotension, Hypoxia, Oxygen Saturation Decreased, Respiratory Rate Increased, Tachycardia
Adverse event was reported on Aug 09, 2010 by a Female patient taking Cyclophosphamide (View Usage) (Dosage: ) was diagnosed with colorectal cancer (What is colorectal cancer?) and. Location: UNITED KINGDOM , 45 years of age, Patient had the following side effects: dyspnoea, hypotension, hypoxia, oxygen saturation decreased, respiratory rate increased, tachycardia. During the same period patient was treated with MFEZ (View Mfez Review and Mfez Label ), FLUDARABINE (View Fludarabine Review and Fludarabine Label ), PROLEUKIN (View Proleukin Review and Proleukin Label ).

6931016-9 | Cholangitis Acute
on Aug 10, 2010 Male patient from CZECH REPUBLIC , 64 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Cyclophosphamide (View Usage). After Cyclophosphamide was administered, patient had the following side effects: cholangitis acute. Cyclophosphamide dosage: . During the same period patient was treated with MABTHERA (View Mabthera Review and Mabthera Label ), FLUDARA (View Fludara Review and Fludara Label ), SUMETROLIM (View Sumetrolim Review and Sumetrolim Label ). Patient was hospitalized.

6930338-5 | Reversible Posterior Leukoencephalopathy Syndrome
on Aug 13, 2010 Female patient from UNITED KINGDOM , 60 years of age, was diagnosed with t-cell lymphoma and was treated with Cyclophosphamide (View Usage). Patient experienced the following unwanted or unexpected effects: reversible posterior leukoencephalopathy syndrome. Cyclophosphamide dosage: . During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6929217-9 | Febrile Neutropenia, Lymphopenia, Pain In Extremity, Thrombocytopenia
Patient was taking Cyclophosphamide (View Usage). Patient had the following side effects: febrile neutropenia, lymphopenia, pain in extremity, thrombocytopenia on Aug 06, 2010 from UNITED STATES Additional patient health information: Male patient , child 6 years of age, weighting 37.48 lb, was diagnosed with neuroblastoma (What is neuroblastoma?) and. Cyclophosphamide dosage: . During the same period patient was treated with PS PRODUCT NOT LISTED (View Ps Product Not Listed Review and Ps Product Not Listed Label ), TOPOTECAN (View Topotecan Review and Topotecan Label ), MORPHINE (View Morphine Review and Morphine Label ), BACTRIM (View Bactrim Review and Bactrim Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), CEFEPIME (View Cefepime Review and Cefepime Label ). Patient was hospitalized.